Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences.
Tohoku J Exp Med. 2020 Dec;252(4):287-296. doi: 10.1620/tjem.252.287.
Wisteria floribunda agglutinin (WFA) is a lectin that binds to the sugar chain of Mac-2 binding protein (M2BP), and WFA-positive M2BP (WFA-M2BP) has been reported as a useful marker for assessing liver fibrosis in chronic liver disease. Tolvaptan (TLV), a selective vasopressin V2 receptor antagonist, is used for cirrhotic ascites in Japan, but good predictors of treatment efficacy remain to be established. Our aim was to investigate whether WFA-M2BP monitoring before and after TLV administration can predict treatment efficacy in patients with cirrhotic ascites. Twenty patients (10 men), with a median age of 72 years, were enrolled. Cirrhosis was caused by hepatitis B virus (n = 3), hepatitis C virus (n = 4), alcohol (n = 8), and others (n = 5). Responders were defined as having a body weight loss of ≥ 1.5 kg/week after TLV administration. Serum WFA-M2BP levels were measured at baseline and days 1, 3, and 7 after TLV treatment. Twelve patients (60%) were responders. Baseline WFA-M2BP levels were correlated with serum albumin levels (r = -0.544, P = 0.013). The baseline furosemide dose was lower and platelet count was higher in responders than in non-responders (P < 0.05). The ratio of WFA-M2BP levels on day 1 after TLV administration to baseline was lower in responders than in non-responders (P < 0.05). The decrease in the ratio discriminated responders from non-responders (AUC = 0.844, P < 0.05). In conclusion, monitoring serum WFA-M2BP is helpful for predicting the efficacy of TLV treatment in patients with cirrhotic ascites.
藤黄凝集素 (WFA) 是一种与 Mac-2 结合蛋白 (M2BP) 糖链结合的凝集素,WFA 阳性的 M2BP(WFA-M2BP)已被报道为评估慢性肝病肝纤维化的有用标志物。托伐普坦(TLV)是一种选择性血管加压素 V2 受体拮抗剂,在日本用于治疗肝硬化腹水,但仍需要建立良好的治疗效果预测指标。我们的目的是研究 TLV 给药前后 WFA-M2BP 监测是否可以预测肝硬化腹水患者的治疗效果。
纳入了 20 名患者(10 名男性),中位年龄为 72 岁。肝硬化由乙型肝炎病毒(n = 3)、丙型肝炎病毒(n = 4)、酒精(n = 8)和其他原因(n = 5)引起。TLV 给药后体重减轻≥1.5kg/周的患者被定义为应答者。在 TLV 治疗前和治疗后第 1、3 和 7 天测量血清 WFA-M2BP 水平。12 名患者(60%)为应答者。基线 WFA-M2BP 水平与血清白蛋白水平呈负相关(r = -0.544,P = 0.013)。应答者的基线呋塞米剂量较低,血小板计数较高(P < 0.05)。TLV 给药后第 1 天 WFA-M2BP 水平与基线的比值在应答者中低于非应答者(P < 0.05)。该比值的降低可区分应答者和非应答者(AUC = 0.844,P < 0.05)。
总之,监测血清 WFA-M2BP 有助于预测 TLV 治疗肝硬化腹水患者的疗效。